Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
10:30pm, Thursday, 29'th Jan 2026
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability
Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript
08:23pm, Thursday, 29'th Jan 2026
Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript
Roche's Full-Year Earnings: Solid, No Alarms - Obesity Promise Makes The Buy Case
11:43am, Thursday, 29'th Jan 2026
Hoffman-La Roche aka Roche Holding AG delivered robust 2025 results, with core EPS up 11% CER and a resilient pharma division driving growth. RHHBY's pipeline, especially in obesity and cardiovascular
RHHBY's 2025 Results Hit by Currency Headwinds, Sales Up 7% at CER
10:51am, Thursday, 29'th Jan 2026
Roche's key drugs lift sales by 7% at CER despite FX headwinds. The company expects mid-single digit sales growth in 2026.
How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity
09:24am, Thursday, 29'th Jan 2026
Roche hopes to rival Eli Lilly and Novo Nordisk in the red-hot weight-loss space. The Swiss drug giant is working on four key drugs.
Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite
06:31am, Thursday, 29'th Jan 2026
Drugmakers Roche and Sanofi posted full-year earnings that matched expectations and did little to move either stock. As pharma companies face a "patent cliff" where existing drugs lose exclusivity, th
Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline
02:06am, Thursday, 29'th Jan 2026
The Swiss drugmaker said it expects sales to grow in the mid-single-digit range, with core EPS growth in the high-single-digit range at constant currencies.
Roche sees high single-digit earnings growth in 2026
01:09am, Thursday, 29'th Jan 2026
Roche ROG.S said on Thursday it expects 2026 group sales to grow in the mid single-digit percentage range, while targeting core earnings per share growth in the high single-digit range.
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
01:00am, Thursday, 29'th Jan 2026
Outlook for 2026 Roche (SIX: RO, ROG; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single
Roche Reports Upbeat Efficacy Data From Phase II Obesity Study
10:16am, Wednesday, 28'th Jan 2026
RHHBY reports encouraging phase II data as CT-388 delivers strong, sustained weight loss and metabolic benefits in adults with obesity or overweight.
Roche's CT-388 Adds Optionality In The GLP Market, But Wait For Dips
08:56am, Wednesday, 28'th Jan 2026
Roche's CT-388 Phase 2 showed competitive 48-week weight loss. I believe this supports a credible late-entry push into the massive obesity/GLP market. Roche's Genentech plans to start its Phase 3 this
Roche Is The 'Value Play' Of The 2026 Obesity Gold Rush
03:56am, Wednesday, 28'th Jan 2026
Roche remains a Buy, driven by strong pipeline progress and conservative valuation, with shares up 36% since my last recommendation. CT388-103's Phase 2 obesity data show placebo-adjusted weight loss
Roche: Important De-Risking Of CT-388 In Obesity, Petrelintide Is Next
01:08pm, Tuesday, 27'th Jan 2026
Roche reported positive phase 2 results for CT-388 in obesity, with competitive efficacy and tolerability to Eli Lilly's tirzepatide. CT-388 delivered 22.5% weight loss at the highest dose after 48 we
Roche's Obesity Drug Helps Almost 87% People Lose At Least 10% Weight
06:21am, Tuesday, 27'th Jan 2026
Roche released Phase 2 trial results showing its weekly obesity drug CT-388 helped patients lose up to 22.5% body weight with strong tolerability and no weight loss plateau at 48 weeks.
Roche Says Weight-Loss Shot Achieved Positive Results in Midstage Trial
02:00am, Tuesday, 27'th Jan 2026
A late-stage trial program of CT-388 is expected to start this quarter.
